Ralliant Corporation
RALRalliant Corporation's price has outrun its earnings. +55.6% in a year against EPS −444.1% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +55.6% in a year while annual EPS moved −444.1% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is between stages while the P/E sits at the 67th percentile of its own 1-year range. Underneath, the last four quarters read deteriorating — profit −33.3% year on year, and 114% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Ralliant Corporation trades at $67.6, between stages. That is +21.6% against its own 200-day average. It sits at 86% of a 52-week range of $40 to $72. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (2 weeks and counting).
Today the stock is between stages. At $67.6 it trades +21.6% versus its 200-day average and sits at 86% of its 52-week range ($40–$72).
Against the market, two honest reads. Cumulative: over the last 1.2 years the stock moved +28% while the S&P 500 moved +23% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-09-04) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Ralliant Corporation trades at 22.1× P/E, mid-range by its own standards (67th percentile). Its long-run median P/E is 21.1×, measured across 0.8 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 22.1× is mid-range by its own standards (67th percentile), against a long-run median of 21.1× measured over 0.8 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −444.1% against a +55.6% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Ralliant Corporation reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 5 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −3.7% | −0.3% | — | — |
| Stock price | +55.6% | — | — | — |
4-Factor Sector Score
58.7/100 — rank 3 of 30 in Electronic Components · 56% evidence confidence
Ralliant Corporation scores 58.7 out of 100 against the 30 companies it is compared with in Electronic Components, ranking 3. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 18.4 + 10 + 11.4 + 18.9 = 58.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Ralliant Corporation reported $0.5 B of revenue in the Apr 26 quarter, +10.4% year on year. Over 3 years it has compounded at −0.3% a year. The last full year, FY25, came in at $2.1 B. The last four reported quarters add to $2.1 B.
FY25 revenue came in at $2.1 B (−3.7% on the year), capping 3 years at −0.3% compound. The latest quarter (Apr 26) printed $0.5 B, +10.4% year on year.
Pace check: the last four quarters averaged +1.2% growth against the decade's −0.3% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Ralliant Corporation's operating margin is 13.2% in the Apr 26 quarter, −1.4 percentage points against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged −57.0% to 23.6%. The current quarter sits inside that band.
The latest quarter's operating margin is 13.2%, −1.4 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged −57.0%–23.6%.
🚨 Why the margin moved: operating margin went −1.4 pp year on year while gross margin went +0.9 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Ralliant Corporation earned $0.0 B of net profit in the Apr 26 quarter, −33.3% year on year. The full FY25 year was a loss of $1.2 B. That is 7.5% of the quarter's revenue. The same quarter a year earlier earned $0.1 B. 1 of the last 9 reported quarters were loss-making.
Apr 26 profit was $0.0 B, −33.3% year on year. On the full year, FY25 printed $−1.2 B (−448.6%).
🚨 Why profit moved: revenue contributed +10.4% and the margin −1.4 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −479.5% vs revenue +1.2%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 114% of Ralliant Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.4 B of operating cash against $−1.2 B of profit. After $0.0 B of capital spending, $0.4 B was left as free cash.
FY25: operating cash of $0.4 B against reported profit of $−1.2 B, leaving free cash of $0.4 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 114% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Ralliant Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Ralliant Corporation earns a ROE of −75% in FY25. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is −58.9% net margin on 0.54× asset turns.
FY25 ROE is −75%.
Why the return is what it is — the wiring (FY25): −58.9% net margin × 0.54× asset turns × 2.34× balance-sheet leverage ≈ −74.4% on equity. Margin does its share; leverage is a meaningful part of the equation.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Ralliant Corporation has 3 quarters of declared dividends on file — too few for a trailing-twelve-month figure. The most recent declaration was $0.05 for Apr 26.
Ralliant Corporation has declared a dividend in 3 of the last 9 reported quarters, most recently $0.05 for Apr 26. That is fewer than four quarters, so no trailing-twelve-month total is shown rather than one built from a partial year.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Ralliant Corporation carries total debt of $1.1 B against shareholder equity of $1.5 B as of Jul 26, a debt-to-equity of 0.75. On the annual view that ratio went from 0.00 in FY23 to 0.71 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jul 26: total debt of $1.1 B against shareholder equity of $1.5 B — a debt-to-equity of 0.75. On the annual view, debt-to-equity went from 0.00 (FY23) to 0.71 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
3.9% of Ralliant Corporation's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 3.1 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 3.9% of the float is sold short, and at typical trading volumes it would take about 3.1 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Ralliant Corporation: the Z-score reads 1.98. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 1.98 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 1.98.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Amphenol CorporationAPH | 70.8/100Favorable setup81% evidence | FADING | 24.7/35 Revenue 54.2% · PAT 61.8% · OPM change 4.2 pp 83% evidence | 21.3/25 ROCE 23.1% · OPM 29.8% 76% evidence | 14.7/20 P/E 42.2× · PEG 0.71 65% evidence | 10.1/20 RS sector -8.9% · RS bench 0.9% · 1Y 24.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 21.3 + 14.7 + 10.1 = 70.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Celestica Inc.CLS | 66.1/100Favorable setup81% evidence | ASLEEP | 26.7/35 Revenue 47.3% · PAT 100% · OPM change 0.4 pp 83% evidence | 16.9/25 ROCE 14% · OPM 9.8% 76% evidence | 15.5/20 P/E 37.8× · PEG 0.62 65% evidence | 7.0/20 RS sector -13.4% · RS bench -4.5% · 1Y 28%0 of 12 weeks ahead 100% evidence |
| Exact sum: 26.7 + 16.9 + 15.5 + 7 = 66.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Ralliant Corporationthis pageRAL | 58.7/100Thin evidence · provisional56% evidence | ASLEEP | 18.4/35 Revenue — · PAT — · OPM change 1 pp 39% evidence | 10.0/25 ROCE 2.1% · OPM 12.7% 76% evidence | 11.4/20 P/E 20.8× · PEG — 15% evidence | 18.9/20 RS sector 8.7% · RS bench 19% · 1Y 55.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 10 + 11.4 + 18.9 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Jabil Inc.JBL | 57.0/100Mixed-positive evidence81% evidence | ASLEEP | 20.7/35 Revenue 17.8% · PAT 49.2% · OPM change 0 pp 83% evidence | 14.3/25 ROCE 9% · OPM 5.1% 76% evidence | 13.8/20 P/E 45.5× · PEG 0.82 65% evidence | 8.2/20 RS sector -7.2% · RS bench 0.2% · 1Y 32.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 14.3 + 13.8 + 8.2 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Allient Inc.ALNT | 56.0/100Thin evidence · provisional60% evidence | FADING | 17.9/35 Revenue 8.7% · PAT 100% · OPM change 0.1 pp 53% evidence | 10.1/25 ROCE 1.8% · OPM 6.7% 57% evidence | 11.3/20 P/E 41.3× · PEG 1.47 65% evidence | 16.7/20 RS sector 17.7% · RS bench 26.7% · 1Y 103.4%10 of 12 weeks ahead 70% evidence |
| Exact sum: 17.9 + 10.1 + 11.3 + 16.7 = 56 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Knowles CorporationKN | 54.7/100Thin evidence · provisional56% evidence | ASLEEP | 20.1/35 Revenue — · PAT — · OPM change 7.4 pp 39% evidence | 9.1/25 ROCE 2.6% · OPM 10.4% 76% evidence | 9.5/20 P/E 53.9× · PEG — 15% evidence | 16.0/20 RS sector 4.3% · RS bench 12.6% · 1Y 55.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 9.1 + 9.5 + 16 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Methode Electronics, Inc.MEI | 54.6/100Mixed-positive evidence64% evidence | FADING | 18.9/35 Revenue -2.8% · PAT — · OPM change 12.9 pp 62% evidence | 5.2/25 ROCE 1% · OPM 3.7% 76% evidence | 11.2/20 P/E 21.4× · PEG — 15% evidence | 19.3/20 RS sector 19.9% · RS bench 27.6% · 1Y 65.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 5.2 + 11.2 + 19.3 = 54.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8CTS CorporationCTS | 54.4/100Thin evidence · provisional56% evidence | ASLEEP | 19.3/35 Revenue — · PAT — · OPM change 2.9 pp 39% evidence | 14.2/25 ROCE 3.9% · OPM 15.8% 76% evidence | 10.7/20 P/E 27.4× · PEG — 15% evidence | 10.2/20 RS sector -6.2% · RS bench 2% · 1Y 36.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 14.2 + 10.7 + 10.2 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Littelfuse, Inc.LFUS | 52.9/100Thin evidence · provisional56% evidence | ASLEEP | 19.1/35 Revenue — · PAT — · OPM change 2.7 pp 39% evidence | 12.0/25 ROCE 3.4% · OPM 15.4% 76% evidence | 9.4/20 P/E 54.9× · PEG — 15% evidence | 12.4/20 RS sector -1.8% · RS bench 5.6% · 1Y 50.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 12 + 9.4 + 12.4 = 52.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Sanmina CorporationSANM | 52.6/100Thin evidence · provisional56% evidence | ASLEEP | 18.7/35 Revenue — · PAT — · OPM change -0.7 pp 39% evidence | 13.3/25 ROCE 5.3% · OPM 3.9% 76% evidence | 9.9/20 P/E 42.3× · PEG — 15% evidence | 10.7/20 RS sector -3.3% · RS bench 4.7% · 1Y 65.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 13.3 + 9.9 + 10.7 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11M-tron Industries, Inc.MPTI | 51.9/100Thin evidence · provisional60% evidence | ASLEEP | 14.5/35 Revenue 9.8% · PAT 12.5% · OPM change 2 pp 53% evidence | 13.6/25 ROCE 4.9% · OPM 17.8% 57% evidence | 13.8/20 P/E 25.9× · PEG 0.98 65% evidence | 10.0/20 RS sector -3.9% · RS bench 4% · 1Y 44.9%6 of 12 weeks ahead 70% evidence |
| Exact sum: 14.5 + 13.6 + 13.8 + 10 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Plexus Corp.PLXS | 51.8/100Thin evidence · provisional56% evidence | ASLEEP | 16.6/35 Revenue — · PAT — · OPM change 0 pp 39% evidence | 11.7/25 ROCE 3.7% · OPM 5.3% 76% evidence | 10.3/20 P/E 40.6× · PEG — 15% evidence | 13.2/20 RS sector 1.8% · RS bench 8.9% · 1Y 71.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 11.7 + 10.3 + 13.2 = 51.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13TE Connectivity plcTEL | 50.7/100Mixed-positive evidence81% evidence | ASLEEP | 20.3/35 Revenue 16.5% · PAT 100% · OPM change 0.1 pp 83% evidence | 15.5/25 ROCE 4.8% · OPM 19% 76% evidence | 7.7/20 P/E 19× · PEG 3.07 65% evidence | 7.2/20 RS sector -23.2% · RS bench -13.4% · 1Y -6.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 15.5 + 7.7 + 7.2 = 50.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Benchmark Electronics, Inc.BHE | 50.7/100Thin evidence · provisional56% evidence | ASLEEP | 18.8/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 9.1/25 ROCE 2.1% · OPM 3.2% 76% evidence | 9.2/20 P/E 67.1× · PEG — 15% evidence | 13.6/20 RS sector 4.5% · RS bench 11.2% · 1Y 84%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 9.1 + 9.2 + 13.6 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Rogers CorporationROG | 49.3/100Thin evidence · provisional56% evidence | ASLEEP | 22.2/35 Revenue — · PAT — · OPM change 5.5 pp 39% evidence | 7.0/25 ROCE 1.5% · OPM 5.3% 76% evidence | 8.9/20 P/E 93.6× · PEG — 15% evidence | 11.2/20 RS sector -0.8% · RS bench 7% · 1Y 57.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 7 + 8.9 + 11.2 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Daktronics, Inc.DAKT | 47.8/100Thin evidence · provisional58% evidence | ASLEEP | 22.1/35 Revenue 10.8% · PAT — · OPM change 7.8 pp 62% evidence | 10.5/25 ROCE 4.1% · OPM 6.8% 76% evidence | 11.1/20 P/E 21.4× · PEG — 15% evidence | 4.1/20 RS sector -27.7% · RS bench -19.1% · 1Y -20.7%0 of 12 weeks ahead 70% evidence |
| Exact sum: 22.1 + 10.5 + 11.1 + 4.1 = 47.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Kopin CorporationKOPN | 47.3/100Thin evidence · provisional51% evidence | ASLEEP | 15.4/35 Revenue -23.5% · PAT — · OPM change -19.6 pp 40% evidence | 5.5/25 ROCE -12.6% · OPM -56.7% 57% evidence | 8.5/20 P/E 181.5× · PEG — 15% evidence | 17.9/20 RS sector 11.7% · RS bench 20.1% · 1Y 61.3%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.4 + 5.5 + 8.5 + 17.9 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Corning IncorporatedGLW | 45.3/100Mixed-negative evidence81% evidence | ASLEEP | 21.4/35 Revenue 19.4% · PAT 100% · OPM change 0.7 pp 83% evidence | 11.2/25 ROCE 2.8% · OPM 15.5% 76% evidence | 6.2/20 P/E 116.6× · PEG 2.64 65% evidence | 6.5/20 RS sector -4.3% · RS bench 1.5% · 1Y 81.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 11.2 + 6.2 + 6.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Universal Display CorporationOLED | 44.5/100Thin evidence · provisional56% evidence | ASLEEP | 14.1/35 Revenue — · PAT — · OPM change -11.8 pp 39% evidence | 13.7/25 ROCE 3% · OPM 30.1% 76% evidence | 11.3/20 P/E 21× · PEG — 15% evidence | 5.4/20 RS sector -41.6% · RS bench -32.5% · 1Y -46.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 13.7 + 11.3 + 5.4 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Flex Ltd.FLEX | 43.6/100Mixed-negative evidence81% evidence | ASLEEP | 14.4/35 Revenue 12.3% · PAT 9.2% · OPM change 0.2 pp 83% evidence | 11.4/25 ROCE 3.7% · OPM 4.9% 76% evidence | 4.7/20 P/E 56.6× · PEG 4.17 65% evidence | 13.1/20 RS sector 8.3% · RS bench 14.2% · 1Y 84%5 of 12 weeks ahead 100% evidence |
| Exact sum: 14.4 + 11.4 + 4.7 + 13.1 = 43.6 · Decision use: Price leads the evidence: RS versus the benchmark is 14.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21Vicor CorporationVICR | 43.5/100Thin evidence · provisional56% evidence | ASLEEP | 16.9/35 Revenue — · PAT — · OPM change 15.1 pp 39% evidence | 13.7/25 ROCE 4.8% · OPM 14.9% 76% evidence | 8.7/20 P/E 121.7× · PEG — 15% evidence | 4.2/20 RS sector -5.3% · RS bench -2.2% · 1Y 247.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 13.7 + 8.7 + 4.2 = 43.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22TTM Technologies, Inc.TTMI | 42.8/100Mixed-negative evidence66% evidence | ASLEEP | 19.9/35 Revenue 25.4% · PAT 84.9% · OPM change 0.9 pp 53% evidence | 10.1/25 ROCE 2.6% · OPM 8.6% 57% evidence | 9.2/20 P/E 47.7× · PEG 1.82 65% evidence | 3.6/20 RS sector -7% · RS bench -2.6% · 1Y 118.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.9 + 10.1 + 9.2 + 3.6 = 42.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23OSI Systems, Inc.OSIS | 35.9/100Mixed-negative evidence66% evidence | ASLEEP | 12.4/35 Revenue 7% · PAT 7.8% · OPM change -1 pp 53% evidence | 12.2/25 ROCE 3% · OPM 11.7% 57% evidence | 5.6/20 P/E 30.3× · PEG 4.61 65% evidence | 5.7/20 RS sector -33.5% · RS bench -24.7% · 1Y -14.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 12.2 + 5.6 + 5.7 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24LSI Industries Inc.LYTS | 34.7/100Thin evidence · provisional60% evidence | ASLEEP | 14.2/35 Revenue 11.5% · PAT 17.4% · OPM change -2 pp 53% evidence | 8.8/25 ROCE 0.9% · OPM 2.7% 57% evidence | 6.8/20 P/E 24.8× · PEG 3.44 65% evidence | 4.9/20 RS sector -20.5% · RS bench -11.9% · 1Y -13%3 of 12 weeks ahead 70% evidence |
| Exact sum: 14.2 + 8.8 + 6.8 + 4.9 = 34.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Ouster, Inc.OUST | 49.7/100Thin evidence · provisional48% evidence | ASLEEP | 22.2/35 Revenue 57.6% · PAT — · OPM change 33.5 pp 40% evidence | 5.7/25 ROCE -8% · OPM -39.5% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.8/20 RS sector -0.5% · RS bench 7.9% · 1Y -1.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 5.7 + 10 + 11.8 = 49.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Richardson Electronics, Ltd.RELL | 48.8/100Thin evidence · provisional50% evidence | ASLEEP | 16.4/35 Revenue — · PAT — · OPM change -1.3 pp 39% evidence | 6.6/25 ROCE 1.9% · OPM 2.7% 76% evidence | 10.4/20 P/E 38.6× · PEG — 15% evidence | 15.4/20 RS sector 4.9% · RS bench 13% · 1Y 64.3%7 of 12 weeks ahead 70% evidence |
| Exact sum: 16.4 + 6.6 + 10.4 + 15.4 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Bel Fuse Inc.BELFB | 46.1/100Thin evidence · provisional50% evidence | ASLEEP | 15.9/35 Revenue — · PAT — · OPM change -3.1 pp 39% evidence | 13.8/25 ROCE 4% · OPM 13.3% 76% evidence | 9.1/20 P/E 85.2× · PEG — 15% evidence | 7.3/20 RS sector -6.9% · RS bench -0.1% · 1Y 65.1%2 of 12 weeks ahead 70% evidence |
| Exact sum: 15.9 + 13.8 + 9.1 + 7.3 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28FabrinetFN | 43.4/100Thin evidence · provisional46% evidence | BASING | 18.4/35 Revenue — · PAT — · OPM change 0.6 pp 24% evidence | 14.2/25 ROCE 5.6% · OPM 10.1% 57% evidence | 9.7/20 P/E 47× · PEG — 15% evidence | 1.1/20 RS sector -33.9% · RS bench -27.6% · 1Y 2.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 14.2 + 9.7 + 1.1 = 43.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29LightPath Technologies, Inc.LPTH | 41.7/100Thin evidence · provisional42% evidence | ASLEEP | 21.5/35 Revenue 87.9% · PAT — · OPM change 15.5 pp 40% evidence | 6.1/25 ROCE -4.4% · OPM -22.2% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -26.3% · RS bench -20.4% · 1Y 29.7%3 of 12 weeks ahead 70% evidence |
| Exact sum: 21.5 + 6.1 + 10 + 4.1 = 41.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Syntec Optics Holdings, Inc.OPTX | 32.9/100Thin evidence · provisional45% evidence | ASLEEP | 11.1/35 Revenue 0% · PAT — · OPM change -19.4 pp 40% evidence | 6.2/25 ROCE -5.6% · OPM -11.9% 57% evidence | 8.6/20 P/E 123× · PEG — 15% evidence | 7.0/20 RS sector -5.2% · RS bench -3.6% · 1Y 274.7%2 of 12 weeks ahead 70% evidence |
| Exact sum: 11.1 + 6.2 + 8.6 + 7 = 32.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Ralliant Corporation's stock price today?
Ralliant Corporation trades at $67.6, +55.6% over the past year. The company is valued at $7.0 B. The stock sits at 86% of its 52-week range of $40–$72, +21.6% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 2 weeks. — as of 17 September 2026.
What were Ralliant Corporation's latest quarterly results?
Ralliant Corporation reported revenue of $0.5 B and net profit of $0.0 B for the Apr 26 quarter. Revenue rose 10.4% and profit fell 33.3% year on year. Earnings per share were $0.39. The operating margin was 13.2%, 1.4 pp lower than a year earlier. — as of 17 September 2026.
What is Ralliant Corporation's revenue?
Ralliant Corporation reported revenue of $0.5 B in the Apr 26 quarter, +10.4% year on year. For the full FY25 fiscal year, revenue was $2.1 B (−3.7%). Over the last 3 years revenue compounded at −0.3% a year. — as of 17 September 2026.
What is Ralliant Corporation's profit?
Ralliant Corporation earned $0.0 B of net profit in the Apr 26 quarter, −33.3% year on year. Full-year FY25 profit was $−1.2 B. The operating margin ran 13.2% in the latest quarter. — as of 17 September 2026.
What is Ralliant Corporation's market cap?
Ralliant Corporation's market capitalisation is $7.0 B at a stock price of $67.6. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Ralliant Corporation's P/E ratio?
Ralliant Corporation trades at a P/E of 22.1×, at the 67th percentile of its own 1-year range, against a long-run median of 21.1×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Ralliant Corporation pay a dividend?
Yes — Ralliant Corporation declared $0.05 per share for Apr 26 (3 quarters on file, too few for a trailing-twelve-month total). — as of 17 September 2026.
What is Ralliant Corporation's dividend per share?
Ralliant Corporation's most recently declared dividend is $0.05 per share for Apr 26. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
Is Ralliant Corporation overvalued?
On its own history, Ralliant Corporation looks expensive: its P/E of 22.1× sits at the 67th percentile of its 1-year range (long-run median 21.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is Ralliant Corporation growing?
Not right now — Ralliant Corporation's latest numbers are shrinking: latest-quarter revenue +10.4% year on year, profit −33.3%, and the margin −1.4 pp at 13.2%. The earnings engine currently reads: deteriorating — as of 17 September 2026.
How is Ralliant Corporation performing?
Ralliant Corporation's latest readings are below. Its latest quarter's revenue rose 10.4% and profit fell 33.3% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
Is Ralliant Corporation beating the market?
Not lately — on a trailing-13-week view Ralliant Corporation is currently behind the S&P 500 (2 weeks and counting; last ahead the week of 2026-09-04), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.2 years the stock moved +28% against the S&P 500's +23% — ahead of the index over the full window. — as of 17 September 2026.
Will Ralliant Corporation's stock price go up?
This page publishes no price forecast for Ralliant Corporation. What it measures instead: the stock price is $67.6. Its P/E of 22.1× sits at the 67th percentile of its own 1-year range. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against Ralliant Corporation?
Somewhat — short interest is 3.9% of Ralliant Corporation's tradable float, about 3.1 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Ralliant Corporation have too much debt?
It is moderate — Ralliant Corporation's debt-to-equity is 0.80. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Ralliant Corporation's capex?
Ralliant Corporation spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 17 September 2026.
What is Ralliant Corporation's cash flow?
Ralliant Corporation generated $0.4 B of operating cash flow in FY25 and $0.4 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $−1.2 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Ralliant Corporation's profit real cash?
Yes — over the last 3 fiscal years, 114% of Ralliant Corporation's reported profit arrived as operating cash. Though the latest year ran at -33% — the trend is the thing to watch. In FY25, operating cash was $0.4 B against reported profit of $−1.2 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Ralliant Corporation?
On the balance sheet, the Z-score reads 1.98 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 17 September 2026.
Where is Ralliant Corporation in its business cycle?
Ralliant Corporation's FY25 operating margin was −57.0%, against a 4-year band of −57.0%–23.6%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 13.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Ralliant Corporation story?
The sharpest disagreement: the price moved +55.6% in a year while annual EPS moved −444.1% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Ralliant Corporation a stock worth studying right now?
This is not investment advice. The machine read: Ralliant Corporation's price has outrun its earnings. +55.6% in a year against EPS −444.1% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!